Stéphane GIBAUD
Stéphane GIBAUD
Verified email at - Homepage
Cited by
Cited by
Medicinal Organometallic Chemistry
R Alberto, C Biot, A Casini, D Dive, PJ Dyson, S Gibaud, A Habtermariam, ...
Topics in Organometallic Chemistry 32, 2010
Increased bone marrow toxicity of doxorubicin bound to nanoparticles
S Gibaud, JP Andreux, C Weingarten, M Renard, P Couvreur
European Journal of Cancer 30 (6), 820-826, 1994
Arsenic-based drugs: from fowler’s solution to modern anticancer chemotherapy
S Gibaud, G Jaouen
Medicinal organometallic chemistry, 1-20, 2010
Microemulsions for oral administration and their therapeutic applications
S Gibaud, D Attivi
Expert opinion on drug delivery 9 (8), 937-951, 2012
Cells involved in the capture of nanoparticles in hematopoietic organs
S Gibaud, M Demoy, JP Andreux, C Weingarten, B Gouritin, P Couvreur
Journal of pharmaceutical sciences 85 (9), 944-950, 1996
Melarsoprol–cyclodextrins inclusion complexes
S Gibaud, SB Zirar, P Mutzenhardt, I Fries, A Astier
International journal of pharmaceutics 306 (1-2), 107-121, 2005
Polyalkylcyanoacrylate nanoparticles as carriers for granulocyte-colony stimulating factor (G-CSF)
S Gibaud, C Rousseau, C Weingarten, R Favier, L Douay, JP Andreux, ...
Journal of controlled release 52 (1-2), 131-139, 1998
Melarsoprol cyclodextrin inclusion complexes as promising oral candidates for the treatment of human African trypanosomiasis
J Rodgers, A Jones, S Gibaud, B Bradley, C McCabe, MP Barrett, ...
PLoS Neglected Tropical Diseases 5 (9), e1308, 2011
Splenic trapping of nanoparticles: complementary approaches for in situ studies
M Demoy, S Gibaud, JP Andreux, C Weingarten, B Gouritin, P Couvreur
Pharmaceutical research 14, 463-468, 1997
Comparison of nanosuspensions and hydroxypropyl-β-cyclodextrin complex of melarsoprol: Pharmacokinetics and tissue distribution in mice
S Ben Zirar, A Astier, M Muchow, S Gibaud
European Journal of Pharmaceutics and Biopharmaceutics 70 (2), 649-656, 2008
Development of microemulsion of mitotane for improvement of oral bioavailability
D Attivi, I Ajana, A Astier, B Demoré, S Gibaud
Drug development and industrial pharmacy 36 (4), 421-427, 2010
Poly (ε-caprolactone) and Eudragit® microparticles containing fludrocortisone acetate
S Gibaud, NJ Al Awwadi, C Ducki, A Astier
International journal of pharmaceutics 269 (2), 491-508, 2004
Preparation of 3, 4-diaminopyridine microparticles by solvent-evaporation methods
S Gibaud, A Bonneville, A Astier
International journal of pharmaceutics 242 (1-2), 197-201, 2002
Cyclodextrin inclusion complexes of the central analgesic drug nefopam
H Brun, M Paul, N Razzouq, M Binhas, S Gibaud, A Astier
Drug development and industrial pharmacy 32 (10), 1123-1134, 2006
A decision support tool facilitating medicine design for optimal acceptability in the older population
T Vallet, E Belissa, S Laribe-Caget, A Chevallier, FX Chedhomme, ...
Pharmaceutical research 35, 1-12, 2018
(2-Phenyl-[1, 3, 2] dithiarsolan-4-yl)-methanol derivatives show in vitro antileukemic activity
S Gibaud, R Alfonsi, P Mutzenhardt, I Fries, A Astier
Journal of organometallic chemistry 691 (5), 1081-1084, 2006
Thiomers and their potential applications in drug delivery
KU Shah, SU Shah, N Dilawar, GM Khan, S Gibaud
Expert Opinion on Drug Delivery 14 (5), 601-610, 2017
Synthesis of S-nitrosoglutathione-alginate for prolonged delivery of nitric oxide in intestines
SU Shah, M Socha, I Fries, S Gibaud
Drug delivery 23 (8), 2927-2935, 2016
Slow-release melarsoprol microparticles
S Gibaud, A Gaia, A Astier
International journal of pharmaceutics 243 (1-2), 161-166, 2002
Acceptability of oral liquid pharmaceutical products in older adults: Palatability and swallowability issues
E Belissa, T Vallet, S Laribe-Caget, A Chevallier, FX Chedhomme, ...
BMC geriatrics 19 (1), 1-9, 2019
The system can't perform the operation now. Try again later.
Articles 1–20